Reply to thread

Message: [QUOTE="Da_Aisijimo_Gou, post: 3985175, member: 264"] Biogen - FDA granted accelerated approval for first new Alzheimers' drug in a few decades, Aducanumab. BIIB trade halted (early morning), was up $22 pre-mkt from Friday's close to $308 before sliding back to $286 before the trading halt. Almost sold near Nov's spike, then BIIB yard sale'd on the FDA's prior negative Aducanumab vote. Tapping fingers awaiting trade restoration ... XBI and other biotech ETFs feeling good on BIIB news. EDIT: Retail trading re-started about 1:30, BOOM up to 468 then reverted back to 428 before another trade halt about 1:50 pm. Sold some shares between 450 and 1 year high of 463. Guaranteed breakeven for rest. Depending on FDA's actual news conference comments regarding additional required, post-approval clinical traials, may buy some more shares if BIIB drops back closer below today's lows. Yoo hoo! [/QUOTE]